Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20765676 | 1.00 | CYP2D6 (0.44) | CYP2D6SRCDPP4F2TSHR | |
| SCHEMBL16924879 | 0.76 | DPP4 (0.39) | CYP2D6SRCDPP4F2TSHR | |
| SCHEMBL11324732 | 0.75 | CYP2A6 (0.42) | ALDH1A1CYP2A6LMNAKMT2A | |
| SCHEMBL743684 | 0.75 | CA1 (0.32) | — | |
| SCHEMBL22498339 | 0.75 | HSD17B10 (0.42) | TSHRCYP2A6LMNAMAPK1 | |
| SCHEMBL11782888 | 0.74 | DPP4 (0.38) | CYP2D6SRCDPP4F2TSHR | |
| SCHEMBL3949902 | 0.74 | DPP4 (0.38) | CYP2D6DPP4F2TSHRLMNA | |
| SCHEMBL3322544 | 0.74 | TSHR (0.38) | CYP2D6SRCDPP4F2TSHR | |
| SCHEMBL28845872 | 0.74 | DPP4 (0.38) | CYP2D6SRCDPP4F2TSHR | |
| SCHEMBL7755282 | 0.73 | ALDH1A1 (0.45) | ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112574138-A | Method for preparing alpha, alpha-fluorobenzyl ketone compound by using photocatalytic microchannel | 南京工业大学 | 2021-03-30 | — | — | CN | claimed |
| CN-105085439-B | A kind of preparation method of epoxiconazole intermediate | 江苏七洲绿色化工股份有限公司 | 2018-03-16 | — | — | CN | claimed |
| CN-105085439-A | Preparation method for epoxiconazole intermediate | JIANGSU SEVENCONTINENT GREEN CHEMICAL CO LTD | 2015-11-25 | — | — | CN | claimed |
| EP-2643000-A2 | THERAPEUTIC PIPERAZINES | Dart Neuroscience (Cayman) Ltd (KY) | 2013-10-02 | — | — | EP | claimed |
| WO-2012040258-A2 | THERAPEUTIC PIPERAZINES | HELICON THERAPEUTICS, INC. (US) | 2012-03-29 | — | — | WO | claimed |
| CN-102040498-A | Method for preparing cyclopropyl o-fluobenzyl ketone | TAIZHOU CITY HWASUN PHARMACUETICAL AND CHEMICAL CO LTD | 2011-05-04 | — | — | CN | claimed |
| US-20110065691-A1 | THERAPEUTIC PIPERAZINES | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2011-03-17 | — | — | US | claimed |
| JP-6135804-A | — | — | None | — | — | JP | disclosed |
| US-20240246965-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE | EQUINORM LTD | 2024-07-25 | — | — | US | disclosed |
| EP-4313985-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE | Equinorm Ltd (FI) | 2024-02-07 | — | — | EP | disclosed |
| CN-117412975-A | Heterocyclic compounds and their use | 伊科诺姆有限公司 | 2024-01-16 | — | — | CN | disclosed |
| CN-114671841-B | Flavanone compound and preparation method and application thereof | 深圳大学 | 2023-09-22 | — | — | CN | disclosed |
| WO-2022207979-A2 | NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE | EQUINORM LTD (FI) | 2022-10-06 | — | — | WO | disclosed |
| WO-2005056498-A2 | METHOD FOR THE PRODUCTION OF 2,3-CIS-SUBSTITUTED 2-ARYL PROPENALS | BASF AKTIENGESELLSCHAFT (DE) | 2005-06-23 | — | — | WO | disclosed |
| JP-H06135804-A | INSECTICIDAL AND MOTHPROOF AGENT COMPRISING POLYFLUOROBENZYL KETONE DERIVATIVE AND INSECTICIDAL AND NOTHPROOF METHOD USING THE SAME | DAINIPPON JOCHUGIKU CO LTD | 1994-05-17 | — | — | JP | disclosed |
| EP-0102227-B1 | 2(1H)-PYRIDINONES, USEFUL AS CARDIOTONIC AGENTS, AND THEIR PRODUCTION | WARNER-LAMBERT COMPANY (US) | 1989-05-03 | — | — | EP | disclosed |
| US-4607037-A | Cardiotonic 2(1H)-pyridinones | WARNER-LAMBERT COMPANY (US) | 1986-08-19 | — | — | US | disclosed |
| US-4503061-A | Substituted phenyl-pyridinones as cardiotonic agents | WARNER-LAMBERT COMPANY (US) | 1985-03-05 | — | — | US | disclosed |
| EP-0102227-A2 | 2(1H)-pyridinones, useful as cardiotonic agents, and their production | WARNER-LAMBERT COMPANY (US) | 1984-03-07 | — | — | EP | disclosed |
| US-4215044-A | FLUORINATION OF AN UNSATURATED SILANOL COMPOUND WITH A PERHALOGENATED HYPOFLUORITE | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1980-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246965-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE | CNR1, CNR2, OPRK1 | CYP2D6 54/4885SRC 1088/4885DPP4 3249/4885 |
| US-20110065691-A1 | THERAPEUTIC PIPERAZINES | PDE4A, PDE4B, PDE4D | CYP2D6 3447/4885SRC 3819/4885DPP4 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.